Detailed Report on Idiopathic Pulmonary Fibrosis - Pipeline Review, H2 2016
Idiopathic Pulmonary Fibrosis - Pipeline Review, H2 2016 is a new market research publication announced by Reportstack. This report provides an overview of the Idiopathic Pulmonary Fibrosis (Respiratory) pipeline landscape.
Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal disease characterized by inflammation and scarring of lung tissue and loss of lung function. Symptoms of IPF include dry cough, shortness of breath, especially during or after physical activity, lasting tiredness and weight loss. Risk factors include smoking, environmental exposure, viral infections, family history and abnormal acid reflux. Treatment includes antioxidants, biological response modulators, anti-fibrotic agents and anticoagulants.
To access full report with TOC, please visit Idiopathic Pulmonary Fibrosis - Pipeline Review, H2 2016
Report Highlights
This report provides comprehensive information on the therapeutics under development for Idiopathic Pulmonary Fibrosis (Respiratory), complete with analysis by stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Idiopathic Pulmonary Fibrosis (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Idiopathic Pulmonary Fibrosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 14, 13, 1, 49 and 8 respectively for Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 4 and 3 molecules, respectively for Idiopathic Pulmonary Fibrosis.
Idiopathic Pulmonary Fibrosis (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from a proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Idiopathic Pulmonary Fibrosis (Respiratory).
- The pipeline guide reviews pipeline therapeutics for Idiopathic Pulmonary Fibrosis (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide reviews key companies involved in Idiopathic Pulmonary Fibrosis (Respiratory) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Idiopathic Pulmonary Fibrosis (Respiratory) therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Idiopathic Pulmonary Fibrosis (Respiratory)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Idiopathic Pulmonary Fibrosis (Respiratory).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Idiopathic Pulmonary Fibrosis (Respiratory) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned
AdAlta Pty Ltd. Aeolus Pharmaceuticals, Inc. Afferent Pharmaceuticals, Inc. Apellis Pharmaceuticals Inc ARMO Biosciences, Inc. Asahi Kasei Pharma Corp. Biogen Inc Bioneer Corporation BiOrion Technologies B.V. Bristol-Myers Squibb Company Celgene Corporation Chrysalis Pharma SAS Compugen Ltd. Cynata Therapeutics Limited F. Hoffmann-La Roche Ltd. FibroGen, Inc. FibroStatin SL Galapagos NV GenKyoTex S.A. GlaxoSmithKline Plc Global Blood Therapeutics, Inc. GNI Group Ltd. HEC Pharm Co., Ltd. Histocell S.L. iBio, Inc. Immunomet Therapeutics, Inc. Inventiva Isarna Therapeutics GmbH Kadmon Corporation, LLC Kasiak Research Private Limited Kolltan Pharmaceuticals, Inc. Kyorin Pharmaceutical Co., Ltd. Lung Therapeutics Inc Moerae Matrix, Inc. MorphoSys AG Novartis AG Nuevolution AB Pharmaxis Limited Promedior, Inc. ProMetic Life Sciences Inc. Pulmatrix, Inc. Respira Therapeutics Inc Ribomic Inc. Saje Pharma, LLC Samumed LLC Sanofi Sorrento Therapeutics, Inc. SPR Biosciences LLC Teva Pharmaceutical Industries Ltd. Therabron Therapeutics, Inc. Vicore Pharma AB Yuhan Corporation
Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal disease characterized by inflammation and scarring of lung tissue and loss of lung function. Symptoms of IPF include dry cough, shortness of breath, especially during or after physical activity, lasting tiredness and weight loss. Risk factors include smoking, environmental exposure, viral infections, family history and abnormal acid reflux. Treatment includes antioxidants, biological response modulators, anti-fibrotic agents and anticoagulants.
To access full report with TOC, please visit Idiopathic Pulmonary Fibrosis - Pipeline Review, H2 2016
Report Highlights
This report provides comprehensive information on the therapeutics under development for Idiopathic Pulmonary Fibrosis (Respiratory), complete with analysis by stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Idiopathic Pulmonary Fibrosis (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Idiopathic Pulmonary Fibrosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 14, 13, 1, 49 and 8 respectively for Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 4 and 3 molecules, respectively for Idiopathic Pulmonary Fibrosis.
Idiopathic Pulmonary Fibrosis (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from a proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Idiopathic Pulmonary Fibrosis (Respiratory).
- The pipeline guide reviews pipeline therapeutics for Idiopathic Pulmonary Fibrosis (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide reviews key companies involved in Idiopathic Pulmonary Fibrosis (Respiratory) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Idiopathic Pulmonary Fibrosis (Respiratory) therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Idiopathic Pulmonary Fibrosis (Respiratory)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Idiopathic Pulmonary Fibrosis (Respiratory).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Idiopathic Pulmonary Fibrosis (Respiratory) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned
AdAlta Pty Ltd. Aeolus Pharmaceuticals, Inc. Afferent Pharmaceuticals, Inc. Apellis Pharmaceuticals Inc ARMO Biosciences, Inc. Asahi Kasei Pharma Corp. Biogen Inc Bioneer Corporation BiOrion Technologies B.V. Bristol-Myers Squibb Company Celgene Corporation Chrysalis Pharma SAS Compugen Ltd. Cynata Therapeutics Limited F. Hoffmann-La Roche Ltd. FibroGen, Inc. FibroStatin SL Galapagos NV GenKyoTex S.A. GlaxoSmithKline Plc Global Blood Therapeutics, Inc. GNI Group Ltd. HEC Pharm Co., Ltd. Histocell S.L. iBio, Inc. Immunomet Therapeutics, Inc. Inventiva Isarna Therapeutics GmbH Kadmon Corporation, LLC Kasiak Research Private Limited Kolltan Pharmaceuticals, Inc. Kyorin Pharmaceutical Co., Ltd. Lung Therapeutics Inc Moerae Matrix, Inc. MorphoSys AG Novartis AG Nuevolution AB Pharmaxis Limited Promedior, Inc. ProMetic Life Sciences Inc. Pulmatrix, Inc. Respira Therapeutics Inc Ribomic Inc. Saje Pharma, LLC Samumed LLC Sanofi Sorrento Therapeutics, Inc. SPR Biosciences LLC Teva Pharmaceutical Industries Ltd. Therabron Therapeutics, Inc. Vicore Pharma AB Yuhan Corporation
Contact:
Debora White
Manager - Marketing
Ph: +1-888-789-6604
​Reportstack Market Research
###
posted by Reportstack @ 08:38
0 Comments
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home